Declan G. Murphy
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Overview
Declan Murphy was co-principal investigator of proPSMA, the randomised trial showing PSMA PET-CT is 27% more accurate than conventional imaging for staging high-risk prostate cancer, the evidence behind PSMA PET's adoption in guidelines. He directs GU oncology at Peter Mac, leads robotic surgery, and chairs the ANZUP theranostics and surgical sub-committees.
| Title | Journal | Year |
|---|---|---|
| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA) | Lancet | 2020 |
| Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis | European Urology | 2020 |
Similar pages
not linked directly; found by shared links- PersonLouise Emmett
Shares European Urology, PSMA, PSMA PET, Prostate cancer and the tag prostate.
- PersonMichael Hofman
Shares proPSMA, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA.
- PersonSilke Gillessen
Shares European Urology, Prostate cancer and the tag prostate.
- PersonShahneen Sandhu
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA, Prostate cancer.
- IdeaNeoadjuvant PSMA radioligand therapy before prostatectomy
Shares the tags prostate, surgery.
- IdeaBispecific PSMA/GRPR radioligands for discordant prostate cancer lesions
- PersonRodney J. Hicks
Shares proPSMA, Peter MacCallum Cancer Centre.
- PersonA. Oliver Sartor
Shares PSMA, PSMA PET, Prostate cancer and the tag prostate.